SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (73)9/14/2000 1:47:59 AM
From: Miljenko Zuanic  Read Replies (1) of 598
 
For a while I am following KDUS/OSIP/SNAP/DDDP/TLRK/ARNA/...work on GPCRs as well as orphan receptors.

However, can't say who has here advantage or whose method is valid and sound, and whose not. Also, what are characteristic of their work and where are difference is so big issue that several studies will not give final answers.

The easy way is to follow specific program (at each company) and see how program progress correlate with what company call *platform* technology.

Miljenko

PS: Need place and time for tomorrow night (if at all)?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News